Piper Sandler Resumes Coverage of Supernus Pharmaceuticals with Overweight Rating
Piper Sandler has resumed coverage of Supernus Pharmaceuticals (SUPN) with an 'Overweight' rating and a price target of $47. The analyst firm highlights that the previously announced merger with Indivior will significantly enhance the combined entity's capabilities in business development and mergers and acquisitions. The move is viewed as a strategic advantage, providing more M&A firepower than either company possessed independently. This outlook suggests positive market sentiment regarding the long-term growth potential and scale resulting from the consolidation.
Topics: Mergers & Acquisitions Stock Ratings
Read the full article at Seeking Alpha
Part of the story Grand Theft Auto VI Achieves Record Pre-order Numbers on PlayStation and Xbox Stores (6 articles)